<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457509</url>
  </required_header>
  <id_info>
    <org_study_id>GPF01</org_study_id>
    <nct_id>NCT00457509</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose
      schedule in immunologically naïve adults against one vaccine formulation without adjuvant in
      terms of tolerance and immunogenicity

      Primary Objective:

      To describe the safety profile and immunogenicity following each injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety of A/H5N1 Inactivated split influenza virus vaccine</measure>
    <time_frame>Entire study period</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Pandemic Influenza</condition>
  <condition>Influenza A Virus Infection</condition>
  <condition>Orthomyxoviridae Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 with Adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 inactivated, split-virion influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 18 to 40 years on day of inclusion

          -  Informed consent form signed

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  For a woman, inability to bear a child or negative urine pregnancy test.

        Exclusion Criteria :

          -  Participation in another clinical trial in the 4 weeks preceding the first trial
             vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Previous participation in a clinical trial involving an investigational flu pandemic
             vaccine.

          -  Vaccination with an influenza vaccine during the past 6 months

          -  Any vaccination in the 4 weeks preceding the first trial vaccination

          -  Vaccination planned in the 4 weeks following any trial vaccination

          -  Breast-feeding.

          -  For a woman of child-bearing potential, the absence of an effective method of
             contraception or abstinence non observed for at least 4 weeks prior to the first
             vaccination and at least 4 weeks after the last vaccination.

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer
             chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic
             corticosteroid therapy.

          -  Known human immunodeficiency virus (HIV), hepatitis B (AgHBs) or hepatitis C
             seropositivity.

          -  Known systemic hypersensitivity to egg proteins, chick proteins, or to any of the
             vaccine components, or history of a life-threatening reaction to the trial vaccine or
             a vaccine containing the same substances.

          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.

          -  Chronic illness at a stage that could interfere with trial conduct or completion.

          -  Current abuse of alcohol or drug addiction that may interfere with the subject's
             ability to comply with trial procedures.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.

          -  Blood or blood-derived products received in the past 3 months.

          -  Febrile illness (temperature ≥ 37.5°C) on the day of inclusion.

          -  Laboratory abnormalities considered clinically significant upon the Investigator's
             judgment in blood sample taken at screening (for Step 1 only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pandemic influenza</keyword>
  <keyword>Avian influenza</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <keyword>A/H5N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

